CymaBay Therapeutics
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$105,370,000 and profit margin reached -339%. Total operating expenses were $132,071,000.

Profit Margin

CymaBay Therapeutics, Inc. (LSE:0I5P.L): Profit margin
2014 0 -31.91M
2015 0 -15.52M
2016 0 -26.67M
2017 10M -27.55M -275.57%
2018 0 -72.54M
2019 0 -102.80M
2020 0 -50.98M
2021 0 -89.99M
2022 0 -106.00M
2023 31.07M -105.37M -339.1%

0I5P.L Income Statement (2014 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue
Revenue
31.07M0000010M000
Cost of revenue
681K710K688K632K800K43.74M12.00M9.74M11.69M11.62M
Gross profit
30.39M-710K-688K-632K-800K-43.74M-2.00M-9.74M-11.69M-11.62M
Operating exp.
Research and development
80.11M67.28M64.54M35.88M83.83M58.12M18.93M15.94M17.02M15.82M
Selling and marketing
00-688K73.00K-800K00000
Total operating expenses
132.07M92.40M86.89M52.67M102.27M32.45M25.09M15.76M3.07M19.61M
Operating income
-101.67M-93.11M-87.58M-53.30M-103.07M-72.50M-21.32M-25.58M-25.89M-24.00M
Other income (expenses), net
-3.69M-12.89M-2.41M2.32M267K-43K-6.23M-1.08M10.36M-7.90M
Income before tax
-105.37M-106.00M-89.99M-50.98M-102.80M-72.54M-27.55M-26.67M-15.52M-31.91M
Income tax expense
0000000000
Net income
-105.37M-106.00M-89.99M-50.98M-102.80M-72.54M-27.55M-26.67M-15.52M-31.91M
Earnings per share
Basic EPS
-0.99-1.21-1.27-0.74-1.53-1.25-0.79-1.14-0.83-2.65
Diluted EPS
-0.99-1.21-1.27-0.74-1.53-1.25-0.79-1.14-0.82-2.65
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData source